Clinical Impact of Peridevice Leak Following Left Atrial Appendage Closure

Left atrial appendage closure (LAAO) has consolidated as a valid strategy for thromboembolic event prevention in patients with non-valvular atrial fibrillation (NVAF), especially in patients with oral anticoagulation contraindication. 

However, the presence of peridevice leak (PDL) following LAAO has raised questions about its long term clinical impact. 

The OCEAN-LAAC, a Japanese multicenter study, prospectively looked at PDL repercussion by transesophageal EKG immediately after procedure and during clinical followup. This analysis focused mainly on leaks deemed “acceptable” (≤3 mm).  

The primary outcome was incidence of thromboembolic events – transient ischemic attack (TIA), ischemic stroke or systemic embolization – within two years after procedure. Secondary end point was all cause mortality at 2 years. 

Read also: Evolution of Renal Denervation at 24 Months.

Data from 1397 patients were analyzed. 6% presented PDL, mean patient age was 77.5, and they were mostly men; mean CHA₂DS₂-VASc score was 4 and HAS-BLED was 3. PDL was observed mostly in patients with elevated baseline heart rate, larger LAA ostial diameter and in most Watchman 2.5 devices, vs FLX.

Ischemic event incidence was significantly higher in patients with any PDL (Gray’s Test, p=0.0036), including those ≤3 mm (sHR: 3.53; CI95%: 1.37–9.04; p=0.016). Altogether, data show the presence of PDL is associated with nearly four times more ischemic events (sHR: 4.25; CI95%: 1.91–9.44; p<0.001).

However, this increase of thromboembolic events does not translate into higher global mortality, probably because of the non-fatal nature of many TIA and ischemic strokes, as well as timely intervention. 

Conclusion

These results suggest that leaks detected after procedure, including those deemed acceptable in size, might have relevant clinical impact on patient prognosis. 

Original Title: Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry.

Reference: Saito T, Tsuruta H, Kajino A, Iwata J, Sakata S, Ryuzaki T, Sago M, Tanaka S, Chatani R, Hachinohe D, Naganuma T, Ohno Y, Tani T, Okamatsu H, Mizutani K, Watanabe Y, Izumo M, Saji M, Mizuno S, Ueno H, Kubo S, Shirai S, Nakashima M, Asami M, Yamamoto M, Ieda M, Hayashida K; OCEAN‐LAAC investigators. Impact of Peridevice Leak on Clinical Outcomes After Left Atrial Appendage Closure: The OCEAN-LAAC Registry. J Am Heart Assoc. 2025 Aug 18:e044422. doi: 10.1161/JAHA.125.044422. Epub ahead of print. PMID: 40820980.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...